8 REFERENCES
1. Whelan J, McTiernan A, Cooper N, et al. Incidence and survival of malignant bone sarcomas in England 1979-2007. Int J Cancer . 2012;131(4):E508-517. doi:10.1002/ijc.26426
2. Daw NC, Neel MD, Rao BN, et al. Frontline Treatment of Localized Osteosarcoma Without Methotrexate: Results of the St. Jude Children’s Research Hospital OS99 Trial. Cancer . 2011;117(12):2770-2778. doi:10.1002/cncr.25715
3. Whelan JS, Bielack SS, Marina N, et al. EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment. Ann Oncol . 2015;26(2):407-414. doi:10.1093/annonc/mdu526
4. Bajpai J, Chandrasekharan A, Talreja V, et al. Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen ‘OGS-12.’ Eur J Cancer . 2017;85:49-58. doi:10.1016/j.ejca.2017.08.013
5. Verma P, Jain S, Kapoor G, Tripathi R, Sharma P, Doval DC. IAP Chemotherapy Regimen Is a Viable and Cost-effective Option in Children and Adolescents With Osteosarcoma: A Comparative Analysis With MAP Regimen on Toxicity and Survival. J Pediatr Hematol Oncol . 2021;43(4):e466-e471. doi:10.1097/MPH.0000000000001946
6. Bishop MW, Chang YC, Krailo MD, et al. Assessing the Prognostic Significance of Histologic Response in Osteosarcoma: A Comparison of Outcomes on CCG-782 and INT0133—A Report From the Children’s Oncology Group Bone Tumor Committee. Pediatr Blood Cancer . 2016;63(10):1737-1743. doi:10.1002/pbc.26034
7. Wadhwa N. Osteosarcoma: Diagnostic dilemmas in histopathology and prognostic factors. Indian J Orthop . 2014;48(3):247-254. doi:10.4103/0019-5413.132497
8. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol Off J Am Soc Clin Oncol . 2002;20(3):776-790. doi:10.1200/JCO.2002.20.3.776
9. Anninga JK, Gelderblom H, Fiocco M, et al. Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer Oxf Engl 1990 . 2011;47(16):2431-2445. doi:10.1016/j.ejca.2011.05.030
10. Marina NM, Smeland S, Bielack SS, et al. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol . 2016;17(10):1396-1408. doi:10.1016/S1470-2045(16)30214-5
11. Li X, Ashana AO, Moretti VM, Lackman RD. The relation of tumour necrosis and survival in patients with osteosarcoma. Int Orthop . 2011;35(12):1847-1853. doi:10.1007/s00264-011-1209-7
12. Harting MT, Lally KP, Andrassy RJ, et al. Age as a prognostic factor for patients with osteosarcoma: an analysis of 438 patients. J Cancer Res Clin Oncol . 2010;136(4):561-570. doi:10.1007/s00432-009-0690-5
13. Picci P, Bacci G, Campanacci M, et al. Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy regional mapping of viable and nonviable tumor. Cancer . 1985;56(7):1515-1521. doi:10.1002/1097-0142(19851001)56:7<1515::AID-CNCR2820560707>3.0.CO;2-6
14. Bacci G, Briccoli A, Ferrari S, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli’s 4th protocol. Eur J Cancer Oxf Engl 1990 . 2001;37(16):2030-2039. doi:10.1016/s0959-8049(01)00229-5
15. Lewis IJ, Nooij MA, Whelan J, et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst . 2007;99(2):112-128. doi:10.1093/jnci/djk015
16. Bacci G, Mercuri M, Longhi A, et al. Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with non-metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution. Eur J Cancer Oxf Engl 1990 . 2005;41(14):2079-2085. doi:10.1016/j.ejca.2005.03.036
17. Ferrari S, Bertoni F, Mercuri M, et al. Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: An analysis of 300 patients treated at the Rizzoli Institute. Ann Oncol . 2001;12(8):1145-1150. doi:10.1023/A:1011636912674
18. Bacci G, Ferrari S, Longhi A, et al. Pattern of relapse in patients with osteosarcoma of the extremities treated with neoadjuvant chemotherapy. Eur J Cancer Oxf Engl 1990 . 2001;37(1):32-38. doi:10.1016/s0959-8049(00)00361-0